1. Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab. (19th July 2017) Authors: Bagel, J.; Tyring, S.; Rice, K.C.; Collier, D.H.; Kricorian, G.; Chung, J.; Iles, J.; Stolshek, B.S.; Kaliyaperumal, A.; Papp, K.A. Journal: British journal of dermatology Issue: Volume 177:Number 2(2017) Page Start: 411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab. (1st August 2017) Authors: Bagel, J.; Tyring, S.; Rice, K.C.; Collier, D.H.; Kricorian, G.; Chung, J.; Iles, J.; Stolshek, B.S.; Kaliyaperumal, A.; Papp, K.A. Journal: British journal of dermatology Issue: Volume 177:Number 2(2017) Page Start: 411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment. (15th July 2016) Authors: Bessette, L.; Khraishi, M.; Kivitz, A.J.; Kaliyaperumal, A.; Grantab, R.; Poulin-Costello, M.; Collier, D. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0198 Immunogenicity associated with a transition from adalimumab reference product to abp 501 in patients with rheumatoid arthritis. (12th June 2018) Authors: Krishnan, E.; Mytych, D.; Zhang, N.; Wang, H.; Kaliyaperumal, A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗